HealthTree Research Publications
HealthTree Cure Hub is a patient data portal where patients can contribute data to accelerate multiple myeloma research. The results of these research projects are then published as abstracts at international conferences and and as manuscripts in medical peer-reviewed journals. To access HealthTree Cure Hub data for multiple myeloma research, go to healthtree.org/research and request a demo.
Pre-Print Publications
The primary aim of disseminating pre-publication research findings is to bring benefits to patients actively engaged in HealthTree Cure Hub. We intend to recognize and appreciate their valuable contributions and participation by granting them early access to potentially valuable information. However, it's important to be aware that the data, interpretations, and final conclusions are subject to change as the research projects expand in sample size and undergo the peer-reviewed publication process.
- IMS 2024 - Ocular complications are common in patients with multiple myeloma receiving dexamethasone: Results of a cross-sectional patient survey
2024 Publications
-
-
ASCO 2024 - Meeting Abstract - Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms.
-
-
-
TNT 2024 - Meeting Poster - Unraveling the Dynamics of Protein Secretion in Multiple Myeloma: A Comparative Study of Non-Secretory Patterns and Disease Evolution (As ASH 2023 Online Only Abstract)
2024 Research Posters
-
ASCO 2024 - Supplement Use Habits and Perceptions in Patients with Plasma Cell Disorders
-
Coach Summit 2024 - Diagnosis disclosure patterns among patients with plasma cell disorders
-
2023 Publications
-
ASH 2023 - Meeting Poster: Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing
-
-
IMS 2023 - Meeting Abstract: Role of Education and Empowerment in Multiple Myeloma patients
-
AJH - Association between dexamethasone exposure and visually significant cataracts in multiple myeloma - Poster Presented at IMS 2023
-
MSSE - Physical Activity and Patient-Reported Outcomes in Monoclonal Plasma Cell Disorders
-
Complementary Therapies in Medicine: Integrative medicine in multiple myeloma and plasma cell disorders
-
-
TCT 2023 Meeting Poster: The Side Effect Prevalence and Severity of Multiple Myeloma Doublet Vs Triplet Induction Therapy: A Retrospective Comparison of Patients Older Than 68 Years.
2023 Research Posters
2022 Publications
-
-
-
The Lancet Haematology: A survey on the patient perspective on cure in multiple myeloma
-
-
-
ASH 2022 Meeting Abstract: What Are the Top Myeloma Patient Concerns at and Since Diagnosis?
2021 Publications
-
-
ASCO 2021 Meeting Abstract: Tandem versus single autologous stem cell transplant: A patient-reported outcome.
-
ASCO 2021 Meeting Abstract: Patient-reported experience platform identifies discordance between guidelines and real-world practice: Maintenance therapy for high-risk multiple myeloma.
-
ASCO 2021 Meeting Abstract: Acute and chronic cancer-related distress among multiple myeloma patients during the COVID-19 pandemic.
-
ASCO 2021 Meeting Abstract: Integrative medicine and plasma cell disorders.
-
ASH 2021 Meeting Abstract: Online patient-reported platform detects trend of increased COVID-19 risk and severity for multiple myeloma patients on active lenalidomide-based therapy
-
ASH 2021 Meeting Abstract: Multiple Myeloma, Clinical Characteristics, and Increased COVID-19 Risk Using Real-World Data
2020 Publications
HealthTree Cure Hub is a patient data portal where patients can contribute data to accelerate multiple myeloma research. The results of these research projects are then published as abstracts at international conferences and and as manuscripts in medical peer-reviewed journals. To access HealthTree Cure Hub data for multiple myeloma research, go to healthtree.org/research and request a demo.
Pre-Print Publications
The primary aim of disseminating pre-publication research findings is to bring benefits to patients actively engaged in HealthTree Cure Hub. We intend to recognize and appreciate their valuable contributions and participation by granting them early access to potentially valuable information. However, it's important to be aware that the data, interpretations, and final conclusions are subject to change as the research projects expand in sample size and undergo the peer-reviewed publication process.
- IMS 2024 - Ocular complications are common in patients with multiple myeloma receiving dexamethasone: Results of a cross-sectional patient survey
2024 Publications
-
ASCO 2024 - Meeting Abstract - Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms.
-
TNT 2024 - Meeting Poster - Unraveling the Dynamics of Protein Secretion in Multiple Myeloma: A Comparative Study of Non-Secretory Patterns and Disease Evolution (As ASH 2023 Online Only Abstract)
2024 Research Posters
-
ASCO 2024 - Supplement Use Habits and Perceptions in Patients with Plasma Cell Disorders
-
Coach Summit 2024 - Diagnosis disclosure patterns among patients with plasma cell disorders
2023 Publications
-
ASH 2023 - Meeting Poster: Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing
-
IMS 2023 - Meeting Abstract: Role of Education and Empowerment in Multiple Myeloma patients
-
AJH - Association between dexamethasone exposure and visually significant cataracts in multiple myeloma - Poster Presented at IMS 2023
-
MSSE - Physical Activity and Patient-Reported Outcomes in Monoclonal Plasma Cell Disorders
-
Complementary Therapies in Medicine: Integrative medicine in multiple myeloma and plasma cell disorders
-
TCT 2023 Meeting Poster: The Side Effect Prevalence and Severity of Multiple Myeloma Doublet Vs Triplet Induction Therapy: A Retrospective Comparison of Patients Older Than 68 Years.
2023 Research Posters
2022 Publications
-
The Lancet Haematology: A survey on the patient perspective on cure in multiple myeloma
-
ASH 2022 Meeting Abstract: What Are the Top Myeloma Patient Concerns at and Since Diagnosis?
2021 Publications
-
ASCO 2021 Meeting Abstract: Tandem versus single autologous stem cell transplant: A patient-reported outcome.
-
ASCO 2021 Meeting Abstract: Patient-reported experience platform identifies discordance between guidelines and real-world practice: Maintenance therapy for high-risk multiple myeloma.
-
ASCO 2021 Meeting Abstract: Acute and chronic cancer-related distress among multiple myeloma patients during the COVID-19 pandemic.
-
ASCO 2021 Meeting Abstract: Integrative medicine and plasma cell disorders.
-
ASH 2021 Meeting Abstract: Online patient-reported platform detects trend of increased COVID-19 risk and severity for multiple myeloma patients on active lenalidomide-based therapy
-
ASH 2021 Meeting Abstract: Multiple Myeloma, Clinical Characteristics, and Increased COVID-19 Risk Using Real-World Data
2020 Publications
Trending Articles
Upcoming Events
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.